Company: INMB
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001213900-25-073077
Chunk: 80

Company: Inmune Bio, Inc.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 2
Chunk 80
---
 impairment assessment, the Company estimated the
asset’s fair value at $0 as of June 30, 2025, resulting in a recorded impairment of $16.5 million.

Other Expense, net

During the three months ended
June 30, 2025, and 2024, the Company recorded $0.1 million of other income due to the Company earning interest income on its cash investments.

31

Comparison
of the Six Months Ended June 30, 2025 and 2024

The following table summarizes
our results of operations for the periods indicated:

    Six Months Ended June 30,  

    (in thousands) 
    2025  
    2024  
    Change 
  
    Revenues 
    $50  
    $14  
    $36 
  
    Operating expenses: 

    Research and development 
     13,443  
     15,746  
     (2,303)
  
    General and administrative 
     4,569  
     5,150  
     (581)
  
    Impairment of acquired in-process research and development intangible assets 
     16,514  
     -  
     16,514 
  
    Total operating expenses 
     34,526  
     20,896  
     13,630 
  
    Loss from operations 
     (34,476) 
     (20,882) 
     (13,594)
  
    Other income, net 
     279  
     111  
     168 
  
    Net loss 
    $(34,197) 
    $(20,771) 
    $(13,426)

Revenues

During the six months ended
June 30, 2025, the Company recognized revenue from a license agreement that was terminated during 2025. During the six months ended June
30, 2024, the Company recognized revenue from the sale of MSC’s.

Research and Development

Research and development expenses
were approximately $13.4 million and $15.7 million during the six months ended June 30, 2025 and 2024, respectively. The change in
research and development expenses during the six months ending June 30, 2025 compared to the six months ending June 30, 2024 is mainly
due to the Company incurring $3.0 million less Alzheimer’s clinical program